ADAM17 and diabetes mellitus: As shown in Figure 4, the protein expression of α-SMA, a unique marker of cardio-myofibroblast, was remarkably increased in DM or DM + Vector groups relative to the NC group, which was blunted by ADAM17-shRNA treatment while raised again to a even higher level by Ad-ADAM17 treatment (Figures 4A,B).